Upfront Cabozantinib for Advanced RCC Improves Outcomes
Cabozantinib reduced the risk of disease progression or death compared with sunitinib among patients with previously untreated advanced renal cell carcinoma.
Cabozantinib reduced the risk of disease progression or death compared with sunitinib among patients with previously untreated advanced renal cell carcinoma.
Rises and decreases in neutrophil-to-lymphocyte ratio at 6 weeks after treatment with anti-PD-1/PD-L1 immune checkpoint blockade is associated with progression-free and overall survival.
Despite low infection rates, AVFs have a high risk of maturation failure and abandonment.
A European trial found a survival benefit from PCa screening and a US trial did not, but a new analysis finds that both trials provide compatible evidence that screening decreases PCa mortality.
Vabomere, which combines meropenem and vaborbactam, demonstrated superior efficacy to piperacillin/tazobactam.
Liraglutide-treated patients were 22% less likely than placebo recipients to experience a composite outcome of renal events.
AKI occurred with similar frequency among patients who did and did not receive contrast medium.
In a study of African Americans with hypertension-related CKD, metoprolol, but neither ramipril nor amlodipine, increased serum uric acid levels.
No significant association found between marijuana use and change in estimated glomerular filtration rate or development of albuminuria.
Bosutinib treatment was associated with a 66% decrease in the annual rate of kidney enlargement.